CN114793434A - 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物 - Google Patents

作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物 Download PDF

Info

Publication number
CN114793434A
CN114793434A CN202080080119.8A CN202080080119A CN114793434A CN 114793434 A CN114793434 A CN 114793434A CN 202080080119 A CN202080080119 A CN 202080080119A CN 114793434 A CN114793434 A CN 114793434A
Authority
CN
China
Prior art keywords
alkyl
substituted
optionally substituted
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080119.8A
Other languages
English (en)
Chinese (zh)
Inventor
孙晖
孙璞
程果
区祺俊
仲明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aten Co
University of California San Diego UCSD
Original Assignee
Aten Co
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aten Co, University of California San Diego UCSD filed Critical Aten Co
Publication of CN114793434A publication Critical patent/CN114793434A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080080119.8A 2019-10-18 2020-10-16 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物 Pending CN114793434A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916983P 2019-10-18 2019-10-18
US62/916,983 2019-10-18
PCT/US2020/055979 WO2021076886A1 (en) 2019-10-18 2020-10-16 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders

Publications (1)

Publication Number Publication Date
CN114793434A true CN114793434A (zh) 2022-07-26

Family

ID=73198494

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080119.8A Pending CN114793434A (zh) 2019-10-18 2020-10-16 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物

Country Status (9)

Country Link
US (2) US11884647B2 (https=)
EP (1) EP4045485A1 (https=)
JP (1) JP2022552019A (https=)
KR (1) KR20220087497A (https=)
CN (1) CN114793434A (https=)
AU (1) AU2020365108A1 (https=)
CA (1) CA3158150A1 (https=)
TW (1) TWI882020B (https=)
WO (1) WO2021076886A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
KR20220087497A (ko) 2019-10-18 2022-06-24 더 리전츠 오브 더 유니버시티 오브 캘리포니아 병원성 혈관을 표적화하기 위한 화합물 및 방법
EP4542755A4 (en) 2022-07-15 2025-11-12 Lg Energy Solution Ltd BATTERY BLOCK AND VEHICLE CONTAINING IT

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072093A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
WO2009019708A2 (en) * 2007-08-09 2009-02-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
CN102124000A (zh) * 2008-06-17 2011-07-13 阿斯利康(瑞典)有限公司 吡啶化合物

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
JPH02262627A (ja) 1988-12-08 1990-10-25 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
JPH0539272Y2 (https=) 1989-03-31 1993-10-05
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
JPH0539272A (ja) 1991-01-09 1993-02-19 Nissan Chem Ind Ltd ピリミジンジオン誘導体および除草剤
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
DE4126244A1 (de) 1991-08-08 1993-02-11 Bayer Ag Massefaerben von kunststoffen
GB9221383D0 (en) 1992-10-12 1992-11-25 Minnesota Mining & Mfg Photothermographic imaging materials and antifoggants therefor
US5374514A (en) 1993-01-06 1994-12-20 Kirk; Mark P. Photothermographic materials
DK122693D0 (da) 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
AUPM425294A0 (en) 1994-03-04 1994-03-31 Australian National University, The In-vitro angiogenesis assay
JPH08157461A (ja) 1994-12-07 1996-06-18 Sankyo Co Ltd スルホン誘導体
US5576338A (en) 1995-02-15 1996-11-19 Merck Frosst Canada, Inc. Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
BR9711816A (pt) 1996-08-01 1999-08-31 Du Pont Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes.
DE19638484A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
DE19638486A1 (de) 1996-09-20 1998-03-26 Basf Ag Hetaroylderivate
ZA986594B (en) 1997-07-25 1999-01-27 Abbott Lab Urokinase inhibitors
US6258822B1 (en) 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
US6504031B1 (en) 1998-08-06 2003-01-07 Milan Bruncko Naphthamidine urokinase inhibitors
US6284796B1 (en) 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
GB9822440D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9822450D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
US6927214B1 (en) 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US6639121B1 (en) 1999-07-29 2003-10-28 Dana-Farber Cancer Institute, Inc. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
US6893812B2 (en) 2000-05-30 2005-05-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Three-dimensional ex vivo angiogenesis system
US6803369B1 (en) 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
WO2002024684A1 (en) 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Quinoline derivatives as antibacterials
JP4307070B2 (ja) 2000-11-17 2009-08-05 バイオモーダ・インコーポレーテツド ５，１０，１５，２０−テトラキス（カルボキシフェニル）ポルフィンを使用する、細胞および組織サンプルにおける前がん症状を検出するための組成物および方法
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0031086D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
WO2004002484A1 (ja) 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. ホスホジエステラーゼ阻害剤
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
CN1856307A (zh) 2003-09-23 2006-11-01 默克公司 喹啉钾通道抑制剂
JP2005126549A (ja) 2003-10-23 2005-05-19 Konica Minolta Medical & Graphic Inc 開始剤、組成物、ラジカル発生方法、平版印刷版作製用感光材料および平版印刷版の作製方法
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
JP2008505920A (ja) 2004-07-08 2008-02-28 グラクソ　グループ　リミテッド 抗菌剤
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
WO2006008644A1 (en) 2004-07-13 2006-01-26 Pfizer Products Inc. Antidiabetic compounds
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP2008515960A (ja) 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ キノリン誘導体
JP2008528598A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
WO2006081182A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
EP1868998B1 (en) 2005-04-01 2016-05-25 VFP Therapies New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007099323A2 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives
WO2007099335A1 (en) 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives for treating cancer
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20090275611A1 (en) 2006-04-07 2009-11-05 Boehringer Ingelheim International Gmbh Compounds Which Modulate The CB2 Receptor
WO2007138112A2 (en) 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2008010061A2 (en) 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
AU2007325872B2 (en) 2006-11-08 2012-12-13 Macrogenics West, Inc. TES7 and antibodies that bind thereto
ATE495153T1 (de) 2006-11-09 2011-01-15 Hoffmann La Roche Arylsulfonylpyrrolidine als 5-ht6-inhibitoren
TWI373467B (en) 2007-01-11 2012-10-01 Academia Sinica New aniline or phenol mustrads linked to dna-affinic molecules or water-soluble aromatic rings and their use as cancer
WO2009008906A2 (en) 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
GB0704906D0 (en) 2007-03-14 2007-04-25 Syngenta Participations Ag Fungicides
EP2147310A4 (en) 2007-04-27 2010-09-08 Univ Rochester COMPOSITIONS AND METHODS OF INHIBITING G-PROTEIN SIGNALING
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8063220B2 (en) 2007-06-22 2011-11-22 Richter Gedeon Nyrt. Sulfonyl-quinoline derivatives
US8679836B2 (en) 2007-10-01 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of monitoring angiogenesis and metastasis in three dimensional co-cultures
WO2009082942A1 (en) 2007-12-19 2009-07-09 Ningbo Institute Of Materials Technology And Engineering, Chinese Academy Of Sciences Polythioetherimides and method for producing thereof
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
DE102008010661A1 (de) 2008-02-22 2009-09-03 Dr. Felix Jäger und Dr. Stefan Drinkuth Laborgemeinschaft OHG Verfahren zur Herstellung von Pyridin-2-Boronsäure und Derivaten davon
JP5371118B2 (ja) 2008-04-30 2013-12-18 興和株式会社 キノリン化合物
WO2011022216A1 (en) 2009-08-17 2011-02-24 High Point Pharmaceuticals, Llc Substituted pyridine derivatives, pharmaceutical compositions, and methods of use to treat oxidative stress
JP2013504325A (ja) 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
BR112012016111B1 (pt) 2010-01-04 2017-06-13 Nippon Soda Co composto heterocíclico contendo nitrogênio, e, fungicida agrícola
WO2011127164A2 (en) 2010-04-08 2011-10-13 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
TWI516264B (zh) 2010-05-06 2016-01-11 臺北醫學大學 芳香醯喹啉化合物
TW201206444A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
WO2011143348A1 (en) 2010-05-11 2011-11-17 Fox Chase Cancer Center Antibodies to tumor endothelial marker 7r
WO2011156557A2 (en) 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
KR101195112B1 (ko) 2010-06-14 2012-10-29 인하대학교 산학협력단 암혈관내피세포의 분리방법 및 배양방법
EP2402338A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2401915A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
MX2012015147A (es) 2010-06-30 2013-05-01 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
MX2012015143A (es) 2010-06-30 2013-07-03 Amgen Inc Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
WO2012021837A2 (en) 2010-08-12 2012-02-16 Senomyx, Inc. Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
RU2443697C1 (ru) 2010-12-21 2012-02-27 Александр Васильевич Иващенко Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US11179500B2 (en) 2011-02-24 2021-11-23 Emory University JAB1 inhibitory compositions for ossification and methods related thereto
KR20140039242A (ko) 2011-05-31 2014-04-01 메르크 파텐트 게엠베하 전해질 제형
WO2013020909A1 (en) 2011-08-05 2013-02-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Materials and methods for the treatment of tauopathies
US9586964B2 (en) 2011-10-28 2017-03-07 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
CN102516232A (zh) 2011-12-14 2012-06-27 无锡美克赛医药科技有限公司 一种ErbB2的小分子选择性抑制剂及其应用
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CN106905297A (zh) 2012-06-15 2017-06-30 加利福尼亚大学董事会 用于脑癌的新颖治疗剂
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR102000211B1 (ko) 2012-10-29 2019-09-30 삼성디스플레이 주식회사 유기금속 화합물 및 이를 포함한 유기 발광 소자
US20160155575A1 (en) 2013-07-25 2016-06-02 Basf Se Methine dyes with large organic counter anion for dye sensitized solar cells
CA2937656A1 (en) 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists
US9573950B2 (en) 2014-03-14 2017-02-21 Abbvie Deutschland Gmbh & Co Kg Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators
EP2982667A1 (en) 2014-08-04 2016-02-10 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Competitive PPAR-gamma antagonists
US20170281611A1 (en) 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
TWI745284B (zh) 2015-01-22 2021-11-11 南韓商艾瑞多斯公司 化合物、彼之製法、及含彼之著色劑
WO2016140803A1 (en) 2015-03-03 2016-09-09 The Trustees Of The University Of Pennsylvania Direct mapping of local director field of nematic liquid crystals at the nanoscale
JP2016162983A (ja) 2015-03-04 2016-09-05 ダイキン工業株式会社 エッチング処理用組成物及びエッチング処理方法
US10745350B2 (en) 2015-07-30 2020-08-18 Calgent Biotechnology Co., Ltd. Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
AR106515A1 (es) 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US10501549B2 (en) 2015-11-30 2019-12-10 Seoul National University R&Db Foundation Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
SG11201805286RA (en) 2015-12-24 2018-07-30 Kyowa Hakko Kirin Co Ltd α,β-UNSATURATED AMIDE COMPOUND
US10081668B2 (en) 2016-04-26 2018-09-25 Northwestern University Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
EP3496774A1 (en) 2016-08-15 2019-06-19 Organovo, Inc. Three dimensional bioprinted tumor models for drug testing
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018068357A1 (zh) 2016-10-13 2018-04-19 西华大学 一类新型sirt2蛋白抑制剂及其在制药中的用途
PL3558321T3 (pl) 2016-12-23 2023-10-23 Felicitex Therapeutics, Inc. Pochodne chinolin jako inhibitory kinaz dyrk1a i/lub dyrk1b
WO2018130184A1 (zh) 2017-01-13 2018-07-19 江苏恒瑞医药股份有限公司 1,2,4-三嗪-3-胺类衍生物、其制备方法及其在医药上的应用
WO2018200498A1 (en) 2017-04-24 2018-11-01 Georgetown University Compositions and methods for analyzing cysteine
WO2018202712A1 (en) 2017-05-03 2018-11-08 Bayer Aktiengesellschaft Trisubstitutedsilylmethylphenoxyquinolines and analogues
CN109422754A (zh) 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019173482A1 (en) 2018-03-06 2019-09-12 Sanford Burnham Prebys Medical Discovery Institute 4-aminoquinoline compounds for the treatment of angiogenesis
WO2021076930A1 (en) 2019-10-18 2021-04-22 The Regents Of The University Of California Plxdc activators and their use in the treatment of blood vessel disorders
US20240118284A1 (en) 2019-10-18 2024-04-11 The Regents Of The University Of California Compositions and methods for detecting plxdc1 and plxcd2 in human tissues
US12590298B2 (en) 2019-10-18 2026-03-31 The Regents Of The University Of California Ex vivo tumor angiogenesis model
KR20220087497A (ko) 2019-10-18 2022-06-24 더 리전츠 오브 더 유니버시티 오브 캘리포니아 병원성 혈관을 표적화하기 위한 화합물 및 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072093A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders
WO2009019708A2 (en) * 2007-08-09 2009-02-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
CN102124000A (zh) * 2008-06-17 2011-07-13 阿斯利康(瑞典)有限公司 吡啶化合物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. V. IVACHTCHENKO, ET AL: "5-HT6 Receptor antagonists.I. Screening of the library of various heterocyclic compounds containing an alkylsulfonyl moiety", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 46, no. 5, pages 274 - 284, XP009178358, DOI: 10.1007/s11094-012-0779-z *
A. V. IVACHTCHENKO, ET AL: "Antagonists of Serotonin 5-HT6 Receptors.VI. Substituted 3-(Phenylsulfonyl)Quinolines, Synthesis and Structure-Activity Relationships", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 48, no. 10, pages 648 - 662 *
DELI SUN, ET AL: "Visible-light-induced multicomponent cascade cycloaddition involving N-propargyl aromatic amines, diaryliodonium salts and sulfur dioxide: rapid access to 3- arylsulfonylquinolines", CHEM. COMMUN., vol. 54, pages 1335 - 1338, XP055758949, DOI: 10.1039/C7CC09410H *
JÁNOS GALAMBOS, ET AL: "4-Ary-3-arylsulfonyl-quinolines as negative allosteric modulators of metabotropic GluR5 receptors: From HTS hit to development candidate", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 26, no. 4, pages 1249 - 1252, XP029409762, DOI: 10.1016/j.bmcl.2016.01.024 *
JANOS GALAMBOS，ET AL: "Discovery of 4-amino-3-arylsulfoquinolines, a novel non-acetylenic chemotype of metabotropic glutamate5 (mGlu5) receptor negative allosteric modulators", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 133, pages 240 - 254 *
LIANGLIANG ZHANG, ET AL: "tert-Butyl Hydroperoxide Mediated Cascade Synthesis of 3-Arylsulfonylquinolines", ORG. LETT., vol. 18, pages 1286 - 1289, XP055758824, DOI: 10.1021/acs.orglett.6b00198 *

Also Published As

Publication number Publication date
JP2022552019A (ja) 2022-12-14
AU2020365108A1 (en) 2022-04-21
US11884647B2 (en) 2024-01-30
WO2021076886A1 (en) 2021-04-22
KR20220087497A (ko) 2022-06-24
TW202128161A (zh) 2021-08-01
EP4045485A1 (en) 2022-08-24
TW202602856A (zh) 2026-01-16
US12612385B2 (en) 2026-04-28
US20240270717A1 (en) 2024-08-15
TWI882020B (zh) 2025-05-01
CA3158150A1 (en) 2021-04-22
US20210147385A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
CN108834412B (zh) 嘧啶及其变体、及其用途
CN102336720B (zh) 2-氨基噻唑衍生物及制备方法和应用
CN109415363B (zh) 用于治疗代谢疾病和癌症的新的线粒体解偶联剂
WO2017215464A1 (zh) 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
US12612385B2 (en) Compounds and methods for targeting pathogenic blood vessels
TW200815398A (en) A novel indazole derivative having spirocyclic structure in the side chain
CN113801073B (zh) 14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用
CN107459476B (zh) 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途
JP7853957B2 (ja) ピラゾールボロン酸化合物、それを含有する医薬組成物、及びそれらの使用
CN112300082A (zh) 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
WO2007036131A1 (en) Carzole sulphamide derivatives and their preparation method
KR20110136888A (ko) 퀴녹살린 유도체 및 양성 및 악성 종양 질병 치료를 위한 이의 용도
CN113880772A (zh) 一类cdk激酶抑制剂及其应用
EP4121031A1 (en) 3-diarylmethylenes and uses thereof
CN107531598B (zh) 用于治疗纤维化和纤维化相关病症的组合物
US12187681B2 (en) Ion channel antagonists/blockers and uses thereof
CN113444078B (zh) 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用
CN115872930B (zh) N-取代3,4-二氢异喹啉-1(2h)-酮衍生物、其组合物及其在药物中的应用
TWI923384B (zh) 用於靶向病原性血管之化合物及方法
CN109384764B (zh) 苯基噻吩磺酰胺类化合物、药物组合物、其制备方法和应用
CN111004107B (zh) 含丙烯酮的取代二氯苯化合物及制备方法与应用
CA2886744C (en) Imatinib derivatives, their preparation and use to treat cancer and bacterial and viral infections
CN100389105C (zh) 取代苯亚甲基环戊酮类衍生物及其应用
CN119118863A (zh) 9-菲酰胺类衍生物及其制备方法与用途
WO2025067317A1 (zh) 一种脂质修饰的核酸化合物、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination